Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Dan Spillane who wrote (1451)	3/3/1999 2:26:00 PM
From: Mr. Stress	Read Replies (1) \| Respond to of 2539

CNBC reporting that rumors of merger are "PROBABLY FALSE". This is quoted from briefing.com.

To: Dan Spillane who wrote (1451)	3/3/1999 3:16:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 2539

Mehta's Sergio Traversa on Monsanto, DuPont: Company Comment Bloomberg News March 3, 1999, 1:02 p.m. ET New York, March 3 (Bloomberg) -- The following is a comment from Sergio Traversa, an analyst with Mehta Partners, on a report in today's New York Times that Monsanto Co. is in preliminary talks to merge with DuPont Co., the biggest U.S. chemicals company. ''You have all the pieces in place for something that might happen,'' Traversa said. ''Whether it happens or not, it's a different story.'' DuPont would benefit from acquiring rights to Monsanto's Celebrex, a new arthritis drug that has potential to become a blockbuster, Traversa said. ''DuPont has clearly stated they will make some move in pharmaceuticals. I'm convinced that DuPont will make some move in 1999.'' Traversa said it's too early to predict how such a combination would be structured because it takes weeks or months to negotiate such a large merger. --Jim Finkle in the San Francisco newsroom (415) 912-2996 /mfr